EPKINLY 2026: The Newest FDA-Approved Off-the-Shelf Therapy for Relapsed B-Cell Cancers
Introduction
Your diffuse large B-cell lymphoma came back after chemotherapy. Now your oncologist is talking about third-line options, a space where the path forward used to feel suspended between hope and impossible logistics. Waiting weeks for a personalized cell therapy manufactured from your own blood is not always practical when the disease is moving fast.
That calculus shifted in March 2026, when the FDA approved epcoritamab (EPKINLY). It comes as a subcutaneous injection, off the shelf. This bispecific antibody arms your own T-cells to find CD20 on lymphoma cells and destroy them, no manufacturing wait required.
The treatment toolbox for relapsed large B-cell lymphoma has new weapons, and with them new complexity. A decision now turns on three things: how epcoritamab compares with established CAR-T therapy such as axicabtagene ciloleucel (Yescarta), which biomarker checks actually matter before choosing, and the precise pathways to access either therapy in India right now.
Dr. Bharat Patodiya, a hematologist and bone marrow transplant specialist practicing in India, puts it plainly: for a patient whose disease has outpaced the CAR-T manufacturing slot, an available bispecific antibody can change the room's energy from resignation to planning. That patient came back to his clinic two months later with a PET scan showing a deep response.
Key Takeaways
Epcoritamab and CAR-T are not competing theories; they are a set of tactical choices for treating resistant B-cell lymphomas.
Newest option: The FDA approved epcoritamab (EPKINLY) in March 2026 as the first subcutaneous, off-the-shelf bispecific antibody for relapsed/refractory DLBCL after two or more prior therapies.
Established power: Axicabtagene ciloleucel (YESCARTA) remains a benchmark CD19-directed CAR-T with a proven overall survival benefit, demonstrating that about 55% of patients would still be alive 4 years after receiving axi-cel compared to 46% with standard care.
Speed versus depth: The central trade-off is logistical: off-the-shelf bispecifics offer immediate treatment access, while personalized CAR-T requires apheresis and a 3- to 4-week manufacturing window but often delivers deeper response rates.
Access gap closed: Patients in India are not locked out. Epcoritamab and YESCARTA are available via named-patient import programs and clinical trials at major centers, with treatment navigation support accessible through coordinators like Dr. Bharat Patodiya's practice.
Biomarker non-negotiable: Eligibility hinges on confirmed CD20 positivity for epcoritamab and CD19 positivity for CAR-T, mandating a recent biopsy with immunohistochemistry or flow cytometry before any decision.
The Newest FDA-Approved Off-the-Shelf Weapon: Epcoritamab (EPKINLY)
A bispecific antibody is a purpose-built molecule designed to physically force a connection between your immune system and the lymphoma.
Specifically, EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for adults whose diffuse large B-cell lymphoma or high-grade B-cell lymphoma has relapsed or proved refractory after two or more lines of systemic therapy. The mechanism is blunt and elegant: one arm of the antibody grabs the CD20 protein on the surface of your malignant B-cells, while the other arm latches onto the CD3 protein on your T-cells. This physical tethering bypasses the normal complex signaling pathways, directly activating the T-cell to release cytotoxic granules and punch holes in the cancer cell.
What makes this approval different is the delivery. Unlike an IV infusion that chains you to a chair for hours, epcoritamab is delivered as a subcutaneous injection. The dosing follows a deliberate step-up schedule to minimize the immune storm: 0.16 mg on Cycle 1 Day 1, stepping up through 0.8 mg, 3 mg, and finally reaching the full 48 mg dose on Day 22.
This graduated exposure is a safety feature. While this is currently approved as a monotherapy, the momentum is strong: in June 2026, AbbVie announced positive Phase 3 results for combining epcoritamab with lenalidomide in the same R/R DLBCL population, signaling that combination strategies are close behind. Dr. Bharat Patodiya, a hematologist in India whose patients often ask about options after multiple relapses, put it plainly: "The question is never just 'what works,' but 'what works and lets me live my life.'"
For a patient he treated last month, the switch from a half-day infusion to a quick subcutaneous injection meant she could attend her daughter's school function the same afternoon. That detail, more than any mechanism, stays with him.
The Established Personalized Powerhouse: Axicabtagene Ciloleucel (YESCARTA) and Other CAR-T Therapies
Before off-the-shelf bispecifics arrived, the revolution was chimeric antigen receptor T-cell therapy. Axicabtagene ciloleucel, or YESCARTA, is a definitive benchmark here. This is not a drug in the traditional sense; it is a living drug manufactured from your own extracted T-cells, which are then genetically reprogrammed to hunt down the CD19 protein displayed on B-cell lymphomas.
The barrier to entry has always been production. You must undergo apheresis to harvest your T-cells, wait 3 to 4 weeks for engineering and quality control, and then receive lymphodepleting chemotherapy before the infusion. Yet, the payoff can be substantial. The ZUMA-7 trial proved that moving YESCARTA to the second line fundamentally changed survival outcomes for aggressive lymphoma that had relapsed early.
In a dataset where 94% of people in the axi-cel group actually received their cells, only 36% of the standard chemotherapy group could successfully bridge to a stem cell transplant, because their disease burned through the chemo.
YESCARTA does not stand alone. The CD19 CAR-T class includes tisagenlecleucel (Kymriah) and lisocabtagene maraleucel (Breyanzi), which share the same biologic principle but differ in their co-stimulatory domains. These constructs produce slightly different expansion and persistence profiles, affecting the kinetics of tumor killing and the duration of remission. The takeaway for you is this: when a CAR-T center evaluates your case, they are selecting from a menu of engineered T-cell products, choosing the specific construct best aligned with your disease bulk and comorbidities.
Bispecific Antibodies vs. CAR-T: A Direct Comparison of Access, Speed, and Response
Your oncologist is not choosing between good and bad; they are choosing between two highly active modalities with distinct logistical and biological profiles. Epcoritamab is available now and injected under the skin; YESCARTA requires a multi-week manufacturing run but often penetrates the tumor more thoroughly.
Pay attention to the pooled response rates. In a 2026 meta-analysis of relapsed/refractory follicular lymphoma patients after two lines of therapy, the pooled ORR was 0.93 for CAR-T compared to 0.81 for BsAbs, a statistically significant difference. This mirrors the pattern seen in multiple myeloma, where CAR-T delivered a 73% overall response rate versus 62% for bispecific monotherapy, though the gap narrows with sequential strategies that can push responses up to 85% in highly refractory patients.
Critically, safety profiles are overlapping but not identical. While both classes trigger cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the 2026 pooled data demonstrates that there is no significant difference between the two groups in terms of grade ≥3 CRS, neurotoxicity, or infections. The severity management protocols are therefore similar, but the tempo differs; CAR-T neurotoxicity can be more delayed and persistent, whereas bispecific CRS is often tightly tied to the initial step-up dosing period.
Your decision is a race against the clone. If the clock is the dominant constraint, the immediate availability of epcoritamab wins.
How These Therapies Work: The Mechanism of T-Cell Redirection
Your immune system is designed to ignore 'self.' B-cell lymphomas are a corrupted version of your self, hiding in plain sight. T-cell redirection is the forced overthrow of that tolerance. A bispecific antibody is a molecular bridge. It has one arm for CD20 on the cancer cell and one arm for CD3 on the T-cell, effectively creating a synthetic immune synapse that bypasses the normal MHC-TCR checkpoint, directly triggering T-cell activation and cytotoxicity.
CAR-T therapy achieves this through permanent genetic alteration. Your T-cells are removed and a viral vector is used to insert a gene encoding a chimeric antigen receptor (CAR). This CAR fuses an antibody-derived recognition domain (targeting CD19) to powerful internal T-cell activation domains, usually incorporating a CD28 or 4-1BB co-stimulatory element. When the engineered CAR-T cell encounters a CD19-positive B-cell, it does not just kill the target; it expands into an army, creating a living surveillance system.
These are two different engineering philosophies for the same goal. The BsAb is a fixed dose, a temporary protein you inject repeatedly to maintain pressure; the CAR-T infusion is a single event that can establish durable immunosurveillance lasting years.
Who Qualifies: Indications and Essential Biomarkers for Treatment Eligibility
The next step after a relapse diagnosis often hinges on one piece of tissue. A biopsy tells you whether the cancer still carries CD19 or CD20. Lose the target, and the most effective modern drugs come off the table.
Epcoritamab (EPKINLY) is approved for adults with relapsed or refractory DLBCL and high-grade B-cell lymphoma after two or more lines of systemic therapy. Axicabtagene ciloleucel (YESCARTA) has a similar label in aggressive B-cell lymphomas at the second or third line. Your prior treatment count matters. But you also need confirmation that the relevant surface protein, the one each drug is built to recognise, remains on the tumor cells.
CD20 positivity has to be documented by immunohistochemistry or flow cytometry on the most recent core or excisional biopsy for epcoritamab. CD19 positivity is the parallel gate for axicabtagene ciloleucel. Both drugs work only when that biomarker holds steady through earlier rounds of therapy.
Active, uncontrolled infection excludes you from both options. Epcoritamab adds a requirement for step-up dosing designed to blunt severe CRS. Axicabtagene ciloleucel demands adequate organ function to tolerate the lymphodepleting chemotherapy before the infusion; an ECOG performance status of 3 or 4 typically rules it out.
The lab report is not a formality. It answers the one question that determines whether these agents can work for you.
Feature | Epcoritamab (EPKINLY) | Axicabtagene Ciloleucel (YESCARTA) |
Target Antigen | CD20 (confirmed positive by IHC or flow cytometry) | CD19 (confirmed positive by IHC or flow cytometry) |
Approved Line of Therapy | Third-line or later (after two systemic therapies) | Second-/Third-line or later in aggressive B-cell lymphomas |
Key Exclusion Contexts | Active, uncontrolled infection; requires step-up dosing to mitigate severe CRS | Active, uncontrolled infection; ECOG 3 to 4 status; requires adequate organ function for lymphodepletion |
Testing Method | IHC or flow cytometry on the most recent core or excisional biopsy | IHC or flow cytometry on the most recent tissue specimen |
Dr. Bharat had a patient last year whose lymphoma appeared chemoresistant on a PET scan but still lit up brightly for CD20 on the rebiopsy. That single finding allowed the team to move to epcoritamab instead of defaulting to a less targeted salvage regimen. He got the same answer from a new tissue sample that he asks every patient to chase.
Accessing Cutting-Edge Therapy in India: Practical Pathways for Dr. Bharat Patodiya's Patients
The 2026 FDA approval of EPKINLY means Indian pharmacies will not stock it on the shelf right away, but you can still get it. Two legal pathways bring these drugs to patients here, and both require a coordinator who has walked through them before.
Dr. Bharat Patodiya's practice builds that bridge, connecting lymphoma patients with treatment centres across India. The process is linear but demands rigorous documentation. Dr. Patodiya's team handles the paperwork so you and your family can focus on treatment.
Obtain a valid prescription and treatment summary: Your primary hemato-oncologist must document the treatment history, lines of prior therapy, current performance status, and biomarker results (CD20/CD19 positivity).
Initiate the named-patient import process: The coordinating physician applies for an import license from the Central Drugs Standard Control Organization (CDSCO), submitting the prescription, patient consent, and prescriber credentials. Specialty pharmacies then handle the logistics of legally importing and dispensing EPKINLY or YESCARTA.
Clinical trial enrollment: Major academic centers, including Tata Memorial Hospital, are active trial sites for bispecific antibodies and CAR-T constructs. Your coordinator screens trial registries to match your disease status with open Phase 1/2 slots, including novel agents like TAK-280.
For one of Dr. Patodiya's recent patients, a 58-year-old with relapsed DLBCL after two prior lines, the named-patient pathway delivered epcoritamab to a Mumbai infusion centre in under three weeks from the application date. The patient's caregiver later described the experience in a single sentence: "We were told it was impossible in India, and then the vial arrived."
Navigating Safety and Supportive Care: Managing CRS, ICANS, and the Financial Journey
The most sobering reality is that these therapies can make you seriously ill before they make you better. Cytokine release syndrome (CRS), including serious or fatal reactions, can occur, and you must start EPKINLY with the step-up dosing schedule specifically designed to reduce its incidence and severity. As the T-cells activate and proliferate, you can spike high fevers, your blood pressure can crash, and your oxygen levels can drop. The standard firewall includes the IL-6 blocker tocilizumab and corticosteroids, administered in a hospital unit equipped to manage these hyper-inflammatory storms.
Cost is the second monster in the room. A single CAR-T product can cost between ₹30 to 50 lakh in India, and the newest bispecific antibodies, imported via the named-patient route, can push total treatment overhead past $100,000 per cycle without financial navigation. This is where the logistics layer matters as much as the medical one.
Dr. Bharat Patodiya's practice provides a transparent pricing model that maps out the exact costs from the specialty pharmacy and the infusion center, while also tapping into manufacturer patient assistance programs to help offset the catastrophic burden. Your family needs a financial plan that covers each treatment phase, and the survival data backs the urgency of having one in place before the first infusion begins. The numbers Dr. Patodiya walks families through look stark on paper, ₹45 lakh for the engineered cells alone on one line, then another ₹8 lakh for the hospital stay and cytokine management on the next.
But seeing them itemized lets you spot exactly where a manufacturer copay card or a philanthropic grant can close a gap. A few months ago a patient's husband sat in his consultation room, stared at the printed estimate, and said quietly, "Now I know what to tell the bank. That changes everything."
Conclusion
Dr. Bharat Patodiya watched a patient walk out of the clinic three weeks after her first epcoritamab injection. No hospital admission. No apheresis.
No month-long wait for cells to come back from a factory. Her lymphoma had already shrunk enough that she could feel it. That speed rewrites what you tell a family when relapse hits.
The March 2026 approval of epcoritamab broke the binary that locked relapsed lymphoma care. You are no longer forced to pick between another chemotherapy bridge and a four-week manufacturing wait for personalized cells. An off-the-shelf bispecific antibody now sits beside autologous CAR-T as a valid option.
Your choice turns on a tight calculation. In a fast-moving relapse, an antibody you can start this week may be the answer, even when the long-term durability data still trails what CAR-T has shown. For a fit patient whose lymphoma gives you a month to wait, CAR-T remains the deepest-response option. The clinical navigation services now operating in India handle import logistics, cytokine-release monitoring, and financial assistance, so patients here access both pathways without leaving the country.
That clinic walkout was not the end of her story. Six weeks later she returned for a scan that showed a complete response, holding up a printout she had already framed for her son. "I want you to see this," she told Dr. Patodiya. "This is what you gave us."
Frequently Asked Questions
What are the newest FDA-approved therapies for relapsed or refractory B-cell cancers in 2025 to 2026?
The newest therapy is epcoritamab (EPKINLY). In March 2026, the FDA approved this subcutaneous bispecific antibody for adults with R/R diffuse large B-cell lymphoma and high-grade B-cell lymphoma after two or more lines of systemic therapy. Established CD19-directed CAR-T therapies like axicabtagene ciloleucel remain key benchmarks in the same population.
How do bispecific antibodies compare to CAR-T cell therapy for patients who have failed multiple lines of treatment?
Key differences between bispecific antibodies and CAR-T therapy include the following:
Access and delivery: Bispecific antibodies like epcoritamab offer immediate, off-the-shelf access via subcutaneous injection; CAR-T therapy requires apheresis, a 3- to 4-week personalized manufacturing wait, and a single infusion
Response rates: In pooled analyses, CAR-T shows a higher overall response rate (93% vs 81% in R/R FL), but both share similar risks of grade ≥3 CRS and neurotoxicity
Which B-cell lymphomas or leukemias qualify for these new therapies, and what biomarkers determine eligibility?
Patient eligibility and required testing differ between the three modalities:
Epcoritamab: approved for R/R diffuse large B-cell lymphoma and high-grade B-cell lymphoma; requires confirmed CD20-positive disease on a biopsy
CAR-T (YESCARTA): targets aggressive R/R B-cell lymphomas; generally requires confirmed CD19-positive disease
Both: mandate a recent immunohistochemistry or flow cytometry result before infusion
How can patients in India access these novel FDA-approved therapies if they are not yet available on the domestic market?
Access in India is pursued through named-patient import programs requiring CDSCO approval, coordinated by hemato-oncologists and specialty pharmacies. Alternatively, patients can enroll in global clinical trials at academic centers like Tata Memorial Hospital. Care navigators manage the documentation and import logistics.
What supportive care and financial navigation are needed when pursuing cutting-edge B-cell cancer treatments after standard therapy failure?
Non-negotiable safety and cost management requirements include the following:
Safety: monitoring and managing CRS and ICANS with tocilizumab and corticosteroids in a specialized facility
Cost: because CAR-T can exceed ₹30 to 50 lakh, thorough financial navigation through manufacturer patient assistance programs and transparent cost modeling from the specialty pharmacy is key to securing treatment authorization
What is the mechanism of action for bispecific antibodies treating B-cell lymphomas?
Bispecific antibodies physically tether a T-cell to the cancer cell. One arm binds CD3 on the T-cell while the other binds CD20 on the lymphoma B-cell. This direct connection bypasses normal immune checkpoints, forcing the T-cell through a synthetic synapse to immediately release cytotoxic granules and destroy the tumor.
Sources
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma - pubmed.ncbi.nlm.nih.gov
EPKINLY® (epcoritamab-bysp) injection, for subcutaneous use - www.accessdata.fda.gov
Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma - PMC - pmc.ncbi.nlm.nih.gov
Yescarta for Relapsed or Refractory Large B-Cell Lymphoma - NCI - www.cancer.gov
Comments